mRNA Pioneer's Path | Explore CureVac's journey as an mRNA therapy innovator, navigating financial challenges while advancing its oncology pipeline and maintaining a strong cash position |
Financial Fortitude | Delve into CureVac's robust financial strategy, including its cash runway extending to 2028 and strategic cost-saving measures aimed at long-term sustainability |
Oncology Breakthroughs | Discover CureVac's promising oncology pipeline, featuring encouraging preliminary results for its CVGBM cancer vaccine and plans for future clinical candidates |
Market Outlook | Learn about analyst perspectives on CureVac, with price targets around $16, reflecting cautious optimism amidst a competitive mRNA therapy landscape |
Metrics to compare | CVAC | Peers Peers - average of corresponding metrics from companies closely matching CVAC: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipCVACPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 51.8% | |
Fair Value Upside | Unlock | 0.0% | 7.2% | Unlock |